Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial

BACKGROUND: Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. OBJECTIVES: To report the 12-month extension of a phase II trial evaluating the efficacy, safety and tolerability of atorvastatin 40 mg/d added to interferon beta-1b (IFNB-1b) in relapsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamm, Christian P., El-Koussy, Marwan, Humpert, Sebastian, Findling, Oliver, Burren, Yuliya, Schwegler, Guido, Donati, Filippo, Müller, Martin, Müller, Felix, Slotboom, Johannes, Kappos, Ludwig, Naegelin, Yvonne, Mattle, Heinrich P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907426/
https://www.ncbi.nlm.nih.gov/pubmed/24497963
http://dx.doi.org/10.1371/journal.pone.0086663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907426/
https://www.ncbi.nlm.nih.gov/pubmed/24497963
http://dx.doi.org/10.1371/journal.pone.0086663

Ejemplares similares